Drug intelligence / Profile preview

Shenmai Injection + DCBI

Development stage
Unknown
Modality
Small Molecules
Administration
Intravenous
01

Overview

Shenmai Injection + DCBI is a combination therapy used in Traditional Chinese Medicine. Shenmai Injection is extracted from Panax ginseng and Ophiopogon japonicus, while DCBI is deproteinized calf blood injection. This combination therapy has been studied for treating mild to moderate Alzheimer's disease and is administered intravenously. In clinical studies, patients with Yin-Qi deficiency were given 60 mL of Shenmai injection and 1.2 g of DCBI once daily, with each treatment course lasting 21 days. The combination has shown significant improvements in cognitive function measures including Mini-Mental State Examination (MMSE), clinical dementia rating, and activities of daily living scale scores compared to conventional treatments.

02

Targets

PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)PPARA (Peroxisome proliferator-activated receptor alpha)CYP1A2 (Cytochrome P450 1A2)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)

Beyond the preview

Go deeper on Shenmai Injection + DCBI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenmai Injection + DCBI.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call